TRDA

Business Context and Reporting Period

Entrada Therapeutics, Inc. (TRDA) is a clinical-stage biopharmaceutical company developing genetic medicines for neuromuscular and inherited retinal diseases using its proprietary Endosomal Escape Vehicle (EEV) platform. This Form 10-Q covers the quarterly period ended March 31, 2026. The Company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Collaboration revenue decreased by $19.7 million (96%) compared to Q1 2025. This was primarily due to the substantial completion of research plan activities for the partnered candidate VX-670 under the Vertex Agreement during the first quarter of 2025.
• Increased Net Loss: Net loss widened by $22.4 million, driven by the significant drop in revenue and a slight increase in operating expenses.
• R&D Spend: Research and development expenses increased by $1.0 million, driven by a $3.9 million increase in direct R&D costs for Duchenne muscular dystrophy (DMD) programs, partially offset by a $2.9 million decrease in unallocated R&D expenses.
• Liquidity: Cash and marketable securities decreased by approximately $40.3 million from the end of 2025, reflecting operating cash burn and investment activity.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Cash Runway: Management believes current cash, cash equivalents, and marketable securities of $254.9 million are sufficient to fund operations into the third quarter of 2027.
• Clinical Milestones:
  • ENTR-601-44 (DMD): Cohort 1 of the ELEVATE-44-201 Phase 1/2 trial met its primary safety endpoint and demonstrated statistically significant functional improvement (Time to Rise velocity). Cohort 2 (12 mg/kg) is enrolling, with topline results expected by end of 2026.
  • ENTR-601-45 (DMD): Cohort 1 dosing initiated; data expected mid-2026.
  • VX-670 (DM1): Vertex is on track to share results from the GALILEO Phase 1/2 trial in the second half of 2026.
  • Ocular Programs: ENTR-801 (Usher syndrome) is the first ocular clinical candidate; a second candidate is expected to be announced in H2 2026.

Risks and Contingencies

• Capital Requirements: The Company expects to incur significant losses for the foreseeable future and will require additional financing to achieve its goals. Failure to obtain capital could force delays or termination of programs.
• Development Risks: The EEV platform is novel and unproven. Clinical trials may fail to demonstrate safety or efficacy, and regulatory approval is uncertain.
• Collaboration Dependence: Future revenue is heavily dependent on the success of the Vertex partnership and potential future collaborations.
• Regulatory and Geopolitical: Risks include potential FDA delays, government shutdowns, and supply chain disruptions related to geopolitical conflicts or trade restrictions (e.g., BIOSECURE Act).

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $41.7 million quarterly operating cash burn against the projected runway to Q3 2027.
• Vertex Revenue Recognition: Confirm the timeline for future revenue recognition under the Vertex Agreement, given the sharp decline in Q1 2026.
• ENTR-601-44 Data: Monitor the upcoming Cohort 2 topline data (end of 2026) to validate the functional improvement signals observed in Cohort 1.
• Financing Needs: Assess the likelihood and timing of future equity or debt offerings required to fund operations beyond late 2027.
• Regulatory Status: Track the status of IND/CTA filings for ENTR-601-50 and ENTR-601-51, and the FDA's response to the ELEVATE-44-102 adult trial design.